← Back to Search

Brain Health Assessment for Dementia

N/A
Waitlist Available
Led By Deborah Barnes, PhD
Research Sponsored by Kaiser Permanente
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No prior diagnosis of dementia (defined from EHR diagnosis codes) and not receiving medications for dementia
Be older than 65 years old
Must not have
Currently receiving hospice care
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months after invitation mailed
Awards & highlights

Summary

This trial is testing a new, cheaper way to detect dementia in primary care settings.

Who is the study for?
This trial is for individuals who are active patients at participating clinics, have not been diagnosed with dementia or Alzheimer's Disease, and aren't on medications for these conditions. They must also have enough data available to calculate what's called an eRADAR score. People currently in hospice care cannot participate.
What is being tested?
The study is testing a new strategy to detect dementia early in primary care settings by using a Brain Health Assessment tool. It aims to be low-cost and patient-friendly while improving the identification of cognitive issues.
What are the potential side effects?
Since this trial involves an assessment rather than medication or invasive procedures, there are no direct physical side effects associated with the intervention being tested.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have never been diagnosed with dementia nor am I on dementia medication.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently in hospice care.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months after invitation mailed
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months after invitation mailed for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
New dementia diagnoses
Secondary study objectives
Clinic "no shows"
Dementia medications
Healthcare utilization
+7 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Brain Health InterventionExperimental Treatment1 Intervention
* Calculate eRADAR scores using EHR data to identify eligible individuals * Invite eligible individuals for brain health assessment visit * Enter results of brain health assessment visit into EHR * Provide summary of results and recommended next steps to the Primary Care Physician and participant
Group II: Usual careActive Control1 Intervention
Individuals who meet eligibility criteria will receive usual care.

Find a Location

Who is running the clinical trial?

Kaiser PermanenteLead Sponsor
551 Previous Clinical Trials
27,687,538 Total Patients Enrolled
10 Trials studying Dementia
194,429 Patients Enrolled for Dementia
University of California, San FranciscoOTHER
2,551 Previous Clinical Trials
15,254,464 Total Patients Enrolled
34 Trials studying Dementia
200,242 Patients Enrolled for Dementia
Deborah Barnes, PhDPrincipal InvestigatorUniversity of California, San Francisco
2 Previous Clinical Trials
1,558 Total Patients Enrolled
1 Trials studying Dementia
1,350 Patients Enrolled for Dementia

Media Library

Brain Health Assessment Clinical Trial Eligibility Overview. Trial Name: NCT05356702 — N/A
Dementia Clinical Trial 2023: Brain Health Assessment Highlights & Side Effects. Trial Name: NCT05356702 — N/A
Brain Health Assessment 2023 Treatment Timeline for Medical Study. Trial Name: NCT05356702 — N/A
Dementia Research Study Groups: Brain Health Intervention, Usual care
~1081 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top